MEREO BIOPHARMA GROUP PL-ADR (MREO) Stock Price, Forecast & Analysis
NASDAQ:MREO • US5894921072
MREO Key Statistics, Chart & Performance
The current stock price of MREO is 0.4026 USD. In the past month the price decreased by -20.35%. In the past year, price decreased by -85.13%.
MREO Technical Analysis
MREO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MREO. MREO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MREO Financial Highlights
Over the last trailing twelve months MREO reported a non-GAAP Earnings per Share(EPS) of -0.26. The EPS increased by 36.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.77% | ||
| ROE | -89.46% | ||
| Debt/Equity | 0 |
MREO Forecast & Estimates
14 analysts have analysed MREO and the average price target is 1.79 USD. This implies a price increase of 343.37% is expected in the next year compared to the current price of 0.4026.
MREO Ownership
MREO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.8 | 397.325B | ||
| AMGN | AMGEN INC | 16.84 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 16.8 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.94 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.16 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.91 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.1 | 20.385B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MREO
Company Profile
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
Company Info
MEREO BIOPHARMA GROUP PL-ADR
One Cavendish Place, Fourth Floor
London W1G0QF GB
CEO: Denise Scots-Knight
Employees: 36
Phone: 443330237300
MEREO BIOPHARMA GROUP PL-ADR / MREO FAQ
What does MEREO BIOPHARMA GROUP PL-ADR do?
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
Can you provide the latest stock price for MEREO BIOPHARMA GROUP PL-ADR?
The current stock price of MREO is 0.4026 USD. The price decreased by -5.02% in the last trading session.
What is the dividend status of MEREO BIOPHARMA GROUP PL-ADR?
MREO does not pay a dividend.
How is the ChartMill rating for MEREO BIOPHARMA GROUP PL-ADR?
MREO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?
14 analysts have analysed MREO and the average price target is 1.79 USD. This implies a price increase of 343.37% is expected in the next year compared to the current price of 0.4026.
What is the Price/Earnings (PE) ratio of MEREO BIOPHARMA GROUP PL-ADR (MREO)?
MEREO BIOPHARMA GROUP PL-ADR (MREO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.26).
What is the market capitalization of MREO stock?
MEREO BIOPHARMA GROUP PL-ADR (MREO) has a market capitalization of 64.07M USD. This makes MREO a Micro Cap stock.